Reta will likely become the #1 selling drug in the world. Good news: People will lose weig

Well SupportedLilly's phase 3 trial for retatrutide showed an average body weight loss of 28.3% over 80 weeks at the highest dose.

Well SupportedRetatrutide targets three receptors (GIP, GLP-1, and glucagon), making it more dynamic than semaglutide (one receptor) and tirzepatide (two receptors).

Partially SupportedWeight lost while taking retatrutide is regained when the drug is stopped.

Not SupportedSide effects, including nausea and gastrointestinal issues, were more frequent with the highest dose (12mg) of retatrutide compared to tirzepatide, leading to an 11.3% dropout rate.

Not Supported